New York: Researchers have identified a gene that can act as a tumour suppressor for acute myeloid leukemia (AML), a blood cancer striking mostly older individuals.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

The finding could be important for investigating how best to target treatment of the deadly disease.

Expression of the protein-coding gene hnRNP K is significantly reduced in AML patients who carry a specific genetic deletion, the findings showed.

"Our data implicates hnRNP K in the development of blood disorders and suggests it acts as a tumour suppressor," said Sean Post, assistant professor at The University of Texas MD Anderson Cancer Centre in the US.

"Both in vivo and in vitro results indicate that hnRNP K achieves this through regulation of key genetic pathways. Our study found that hnRNP K expression must be maintained for proper cellular regulation and to prevent tumour formation," Post said.

Through use of a mouse model and cell lines, Post's team showed that reduced activity of this gene was associated with blood cancer. 

The study was published in the journal Cancer Cell.